{"schema_version":"secwatch.filing_event.v1","accession":"0001549595-23-000039","form_type":"8-K","ticker":"NRIX","cik":"0001549595","company_name":"Nurix Therapeutics, Inc.","filed_at":"2023-07-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.267874+00:00","generated_at":"2026-06-13T08:43:28.188185+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Nurix Q2 net loss narrows to $24.3M ($0.45/sh) on $30.7M revenue; Gilead pays $20M for IRAK4 license","bullets":["Net loss of $24.3M ($0.45 EPS) vs $45.4M ($1.01 EPS) in prior year; revenue $30.7M vs $11.4M.","Cash and marketable securities $308.6M as of May 31, 2023, down from $325.6M on Feb 28, 2023.","Gilead exercised option on NX-0479 (IRAK4 degrader) for $20M; up to $425M in milestones + royalties.","Phase 1b expansion started for NX-2127 in DLBCL and MCL; Phase 1a data for NX-5948 expected H2 2023.","NX-2127 and NX-5948 preclinical data showed potent activity against BTKi resistance mutations at AACR and ICML."],"urls":{"canonical":"https://secwatch.observer/filing/0001549595-23-000039","json":"https://secwatch.observer/filing/0001549595-23-000039.json","markdown":"https://secwatch.observer/filing/0001549595-23-000039.md","text":"https://secwatch.observer/filing/0001549595-23-000039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1549595/000154959523000039/0001549595-23-000039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1549595/000154959523000039/nrix-20230713.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T08:43:28.188185+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"30dacd8811ba1f4cc9aed8d2b98cde6a72b3a060","claim":"Nurix Therapeutics, Inc. reported the fiscal quarter ended May 31, 2023 results: revenue $30.7 million.","evidence_excerpt":"Revenue for the three months ended May 31, 2023, was $30.7 million compared to $11.4 million for the three months ended May 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959523000039/0001549595-23-000039-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal quarter ended May 31, 2023"},{"label":"Revenue","value":"$30.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}